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Introduction
Hematopoietic stem cells (HSCs) are the prototype stem cells en-
dowed with the potential of  restoring hematopoiesis in patients 
with hematological malignancies. Clinical transplantation results 
are best obtained by HLA identical donor or closely related donor.
In spite of  nearly 13 million registered volunteer donors world-
wide, nearly half  of  the patients do not have a closely matched 
HLA donor and two-thirds of  patients do not get suitable related 
donor. In such a situation, availability of  unrelated donor (URD) 
from bone marrow (BM), peripheral blood stem cells (PBSC) and 
umbilical cord blood (UCB) escalate the applicability of  HSCT.
Though BM and PBSC transplantation have proven record of  
success, only 40-50% of  unrelated BM and PBSC donor setting 
provide prompt graft source for patients [1]. In the early 1980s, 
Broxmeyer et al introduced UCB as a potential source of  HSCs 
and progenitor cells which provided impetus to perform the first 
UCB transplant for a patient with fanconi anemia in 1988 [2, 3]. 
The paucity of  HSCs in UCB grafts has been a major limitation 
of  UCB transplantation. UCB grafts have been shown to contain 
ten-fold lower cellular dose (nucleated and CD34+ cells) com-
pared to BM and PB transplantation, which has translated into 
delayed engraftment and immune reconstitution [4]. However, 
there is a recent report that demonstrates that there are actually 
more HSCs in UCB than previously realized [5]. A brief  exposure 
to ambient oxygen in native conditions of  hypoxia reportedly de-
creases recovery of  long-term repopulating HSCs and increases 
progenitor cells in UCB. HSC collection in grossly hyperoxic con-
ditions compared to the BM microenvironment [6] compromises 
the survival of  HSCs through the induction of  the mitochondrial 
permeability transition pore (MPTP) and ROS production. The 
MPTP inhibitor cyclosporin. A protects HSCs during collection 
in air, allowing collection of  more number of  HSCs in UCB for 
potential clinical benefit [5].
In unrelated UCB banks, UCB units are rapidly available as “off  
the shelf ” product for narrowing the gap of  a growing popu-
lation of  patients who do not have an identified HLA matched 
relative. Moreover, use of  a frozen graft allows scheduling of  
stem cell collections and date of  transplant without losing repop-
ulation capacity on post-thawing [7]. Frozen UCB units can be 
stored for long duration and then thawed for efficient recovery 
of  HSCs and progenitor cells in relevance to UCB banking and 
transplantation, Broxmeyer et al. evaluated recovery of  function-
ally-intact hematopoietic progenitor cells for up to 23.5 years in 
comparison to pre-freeze numbers from the same donor. Highly 
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efficient recovery (80%-100%) consisting of  highly proliferating 
multipotential hematopoietic progenitors and granulocytes was 
obtained. CD34+ cells isolated from UCB cryopreserved for up to 
21 years showed recovery of  self-renewing HSCs, differentiated 
T-lymphocytes and endothelial colony forming cells [8]. Also, 
these UCB units are tested for infectious diseases prior to stor-
age and are HLA-typed. In comparison with BM or PB graft, 
UCB have less stringent HLA matching requirements, which al-
lows the use of  UCB units with greater mismatch [9]. Permissive 
HLA mismatching allows searching of  a suitable unit for even 
racial or ethnic minorities. Non-invasive procedure to acquire 
UCB cells [10]; lack of  risk to the donor, and lower risk of  acute 
and chronic graft-versus-host disease (GVHD) in pediatric pa-
tients following UCBT are value-added advantages compared to 
BMT and PBSCT [11]. However, initial hope has been tempered 
by low immune reconstitution in case of  UCB graft compared to 
other sources such as BM and PBSC. Total nucleated cells (TNCs) 
and CD34+ cells dose in UCB unit are predominant decisive fac-
tors for engraftment and survival after UCBT [12-14]. The aver-
age TNC dose in a UCB graft is less than ten-fold if  compared 
with average BM graft. Patients who received cell doses less than 
1.8×107 TNCs and 1.7×105 CD34+ cells per kilogram of  the re-
cipient body weight had inferior engraftment and survival rates 
[14]. This contributes to increased risk of  graft failure, delayed 
immune reconstitution and higher transplant related mortality 
[14, 15]. The recovery times for neutrophils (>500 cells/mm3) 
and platelets (20,000 cells/mm3) were both delayed for UCBT re-
cipients compared to BMT recipients (27 days versus 18 days and 
60 days versus 29 days) [9, 16]. The cumulative incidence of  non-
engraftment after UCBT varies from 10 to 20%. Furthermore, 
the non-availability of  donor lymphocyte infusions prevents ap-
plication in post-transplant cellular immunotherapy to invigorate 
donor-derived immunity to treat infections, mixed chimerism, and 
disease relapse [9].
Single Umbilical cord blood transplantation
Initial reports on the use of  UCB as a donor type for hemat-
opoietic cell transplantation were based on the use of  single UCB 
grafts and largely limited to paediatric patients [12, 14, 17-20]. The 
cohort of  the Cord Blood Transplantation (COBLT) prospective 
study in 191 paediatric patients resulted in 57% overall survival 
(OS) at 1 year and 77% for very high-risk patients [21]. Results 
were confirmed with studies from registry and single-centre 
analysis displaying disease-free survival (DFS) of  50%-60% with 
early-stage and 10%-30% with advanced-stage of  disease, thus 
demonstrating favorable outcomes in children with malignant 
and non-malignant hematological diseases. Further, a compara-
tive pediatric study of  99 patients with acute leukemia transplant-
ed with myeloablative UCB graft and 262 MUD BM transplants 
showed significantly reduced rates of  acute and chronic GVHD 
[20]. However, study resulted in delayed neutrophil (32 versus 18 
days) and platelet (81 versus 29 days) recovery times in UCB graft 
recipients. After promising results in children, the initial UCBT 
experience with adults was poor [22]. Developments in adult sin-
gle UCBT followed over the next years with advanced supportive 
care and higher infused cell dose [23, 24].
Double umbilical cord blood transplantation
Further, it was realized that the salient features for effective en-
graftment in both pediatric and adult patients in UCBT are the 
cell dose (TNC or CD34+ cells) and HLA-matching of  the graft 
[25, 26]. Eurocord reported that when a single UCB unit (6/6 
or 5/6 HLA-matched) does not contain adequate number of  
cells (TNC > 2.5×107/kg), double UCB unit is recommended, 
to achieve a combined TNC dose > 3.0×107/kg [25]. Barker et 
al. [27] suggested that if  the UCB unit is only 4/6 HLA matched, 
then the cell dose should be as high as 5.0×107 per kg. Even high-
er doses are recommended if  the single UCB unit is only 4/6 
HLA-matched. In another study, two UCB units, each of  which 
has no more than 2/6 HLA mismatches (low resolution typing of  
HLA-A and -B or high resolution typing of  HLA-DRB1) were 
infused into adults and large children [15, 28]. The recipients of  
1-antigen-mismatched UCB units with a lower cell dose showed 
similar engraftment to 2-antigen-mismatched units. 1-antigen-
mismatched UCB units with a higher cell dose showed superior 
engraftment [20]. Study showed that UCB dose is more important 
factor for engraftment after UCBT than the HLA mismatch. It 
was further suggested that UCB unit selection need to be done 
by considering matching at HLA-C for units that are matched at 
HLA-A, -B, -DRB1 or in the presence of  a single locus mismatch 
at HLA-A, -B or DRB1 [29, 30].
Utilization of  double UCBT platform disseminated extensively 
allowing treatment for large children patients as well as adult pa-
tients, applying various preparative regimens and post-transplant 
immunosuppression [31-34]. Recently, a study showed superior 
OS, DFS and similar transplant related mortality (TRM) in pa-
tients who received double UCB units compared with single 
UCBT [35]. A lower relapse risk was noticed in patients receiv-
ing two CBUs for acute leukemia, possibly through an enhanced 
graft-versus-leukemia effect [36]. Phase I clinical trials in 23 adult 
leukemic patients who received double UCB units following my-
eloablative conditioning, displayed long-term hematopoiesis from 
single UCB donor in 76% patients at day 21 and in 100% pa-
tients by day 100. Initially, both units contribute for engraftment, 
finally, only one UCB predominates [28]. Although reasons are 
not yet clearly elucidated, the implication of  immune mediated 
mechanisms has been suggested [37]. CD3+ cell dose was the only 
factor associated with single unit predominance [38]. To amelio-
rate clinical outcomes after UCBT, a contemporary approach of  
reduced intensity conditioning (RIC) regimens emerged involving 
administration of  high-dose cyclophosphamide, fludarabine, mel-
phalan, rabbit anti-thymocyte globulin and low-dose total body 
irradiation before transplantation [39]. Blood and Marrow Trans-
plant Clinical Trial Network conducted two parallel multicentre 
prospective phase II clinical trials for patients without a suitable 
related donor. The preparative RIC regimen incorporated cyclo-
phosphamide, fludarabine, and 200 cGy of  total body irradiation 
in both trials, dUCBT (BMT-CTN 0604) and haplo-BMT (BMT-
CTN 0603). Although, 1-year cumulative TRM was higher after 
UCBT and lower in haplo-marrow transplant (24% versus 7%), 
however, relapse rate was higher after haplo-marrow transplanta-
tion (31% versus45%). 1-year probability of  OS and progression-
free survival (PFS) recorded was 54% and 46% after dUCBT, 
whereas 62% and 48% in case of  haplo-BMT, respectively. The 
CI of  grade II-IV acute GVHD was 40% after dUCBT and 32% 
following haplo-BMT at day 100. The CI of  neutrophil recovery 
was 94% after dUCBT and 96% after haplo-BMT at day 56. Hap-
lo-BMT showed much better consequences (less GVHD, TRM 
and high OS, PFS) compared to dUCBT. Number of  patients in 
BMT-CTN trials were relatively small and non-randomized, so 
larger follow-ups are needed [40]. Results showed efficacy and 
safety of  study. These phase II trials endorsed the value of  dou-
ble UCBT as an alternative donor source and set the stage for a 
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multi-center, phase 3 randomized trial with RIC and dUCBT ver-
sus HLA haplo-BMT for patients with hematologic malignancies 
(BMT-CTN 1101).
The major disadvantage of  using double cord blood transplants is 
that it is associated with the increased level of  GVHD compared 
to that of  single cord blood transplants [41]. Also, current studies 
demonstrated no significant variation in the rate of  engraftment 
in patients receiving one or two CBUs [28, 41]. Double UCB units 
significantly increase cost and demand on cord banks to collect 
more units. Therefore, it may be best to find a way to get back 
to single cord blood transplants. A recently reported prospective, 
multicenter, randomized, phase III comparative study showed 
similar outcomes in pediatric patients [42]. Results showed that 
similar overall rate of  engraftment (89% versus 86%), chronic 
GVHD (28% versus 31%), risk of  relapse at 1 year (12% versus 
14%), or disease-free survival (68% versus 64%) in single versus 
double UCBT. Even by double UCBT, the number of  useful cells 
obtained were limited and the kinetics of  mature blood cells re-
covery after transfusion were not ideal, so these cells showed little 
direct therapeutic benefits for period up to 3 weeks. These limita-
tions to stem cell transfusion are tackled by approach of  ex vivo or 
in vivo expansion of  UCB cells before infusion to enhance their 
quality and usefulness for transplantation.
Ex vivo expansion of  UCB cells
UCB cells show high regenerative potential because of  longer tel-
omere lengths and high cytotoxicity due to rich density of  primi-
tive nature killer cells, therefore, current strategies are focused on 
the development of  technologies to generate greater numbers 
of  hematopoietic stem and progenitor cells (HSPCs) from given 
fixed cellular yield obtained from an individual UCB unit [43]. 
There are currently numerous approaches under investigation 
that include co-infusion of  accessory cells with UCB cells, notch 
mediated expansion, and utilization of  small molecular weight 
compounds to achieve ex vivo expansion [44]. 
Cytokine-mediated expansion
With consistent efforts to achieve cytokine mediated ex vivo ex-
pansion since a decade, cytokine-mediated expansion methods 
have been translated to the clinic for autologous and allogeneic 
uses. As cytokines result in expansion of  mature HSCs, it is ex-
pected that these committed progenitor cells would enhance ab-
solute neutrophil count recovery. In a study, CD34+ cells were 
isolated from fraction of  UCB unit (40-60%) and expanded in 
liquid culture with cytokines (SCF, G-CSF, TPO, and megakaryo-
cyte growth and differentiation factor, MGDF) in vitro. Expanded 
CD34+ cells were co-infused with non-expanded units to 37 pa-
tients (median TNC dose of  0.99 × 107/kg) following myeloabla-
tive conditioning. This approach resulted in 28 days (range, 15-49) 
for neutrophil recovery and 106 days (range, 38-345) for platelet 
recovery. Thus, study showed similar duration for hematopoietic 
recovery compared with non-expanded UCB unit [45]. 40% of  
patients developed grade III-IV acute GVHD. Study showed fea-
sibility but failed to achieve an improvement in neutrophil and 
platelet engraftment.
The efficacy of  cytokines demonstrated clinical relevant expan-
sion when they were considered in the context of  specific cellular 
response of  low oxygen concentration. CD34+ cells from UCB 
were cultured with cytokines SCF, Flt-3 ligand, TPO and G-CSF 
in anti-oxidant media for 14 days. TPO stabilize transcription 
factor ‘hypoxia-inducing factor-1α’ through generation of  mito-
chondrial reactive oxygen species. Study resulted in an extensive 
amplification of  total cells (CD45+, CD33+, CD19+ cells by ~350-
fold), committed progenitors (colony-forming cells, ~130-fold) 
and CD34+ cells (~100-fold) [46]. Similar study was performed 
using MGDF in place of  TPO for 12 days. Hypoxic culture re-
sulted in 400-fold hematopoietic expansion of  total cells, 80-fold 
for CD34+ stem cells and 150-fold committed progenitors [47]. 
This protocol is already employed in an ongoing clinical trial 
(NCT01034449). Ex vivo expanded UCB graft by this procedure 
proved advantageous for long-term hematopoietic reconstitution 
to generate rapid, complete and sustained donor engraftment in 
transplanted patients [48]. Recently, a novel small molecule ago-
nist of  c-MPL-NR-101, exhibited an even more pronounced ef-
fect on the HSPCs than TPO alone [49].
Co-infusion of  UCB unit with haploidentical mesenchymal 
stromal cells
Co-culture with supporting matrix of  mesenchymal stromal cells 
(MSCs) bestows BM stromal microenvironment to promote 
proliferation and differentiation of  hematopoietic cells. MSCs 
cause immunosuppression as they reduce T-cell proliferation 
and secrete cytokines [50]. Exact mechanisms remain unknown. 
Thus, MSCs along with HSCs are considered to serve in lower-
ing GVHD and improve engraftment rates [51]. Using double 
UCBT platform and a myeloablative conditioning regimen, Shpall 
and colleagues conducted phase I clinical trial by combining un-
manipulated UCB unit (Elizabeth J. Shpall, University of  Texas 
M.D. Anderson Cancer Center, oral communication, November 
5, 2010) with a unit that has been expanded in co-culture with 
cytokines (SCF, Flt-3 ligand, G-CSF, and TPO) and either third-
party haploidentical family member MSCs or “off-the-shelf ” 
MSCs (NCT00498316). Co-culture facilitated 40-fold expansion 
of  hematopoietic cells. On day 14, expanded unit was infused fol-
lowing the infusion of  the un-manipulated UCB unit. Long-term 
engraftment was provided by the unexpanded unit in the major-
ity of  patients by 11 months after transplantation. Median time 
of  15 days (range, 9-42) for neutrophil engraftment in 31 (97%) 
patients and median time of  40 days (range, 13-62) for platelet 
engraftment in 26 (81%) patients was observed. One patient died 
before engraftment [52]. Though no enhancement in engraftment 
was detected, study provided the rationale that UCB could be ex-
panded in MSC co-culture prior to transplantation and set the 
stage for a randomized trial to compare un-manipulated double 
UCB transplantation in which one of  the units is expanded in 
MSC co-cultures. In another study examining MSCs potential, 
eight patients received haploidentical MSCs (median dose 2.1×106 
/kg in addition to UCB (median TNC 3.1×107/kg) on the day 
of  UCB transplant and three patients received additional dose of  
MSCs on day 21. There were no harmful side effects related to 
infusion of  MSCs. All patients achieved neutrophil recovery at 
a median of  19 days (range, 9-28 days) and six patients achieved 
platelet engraftment at a median of  53 days (range, 36-98 days). 
With a median follow-up of  6.8 years, 5 patients remained alive 
and disease free. Rates of  engraftment, GVHD and survival were 
reportedly comparable to historic groups with no serious adverse 
effects with MSC infusion [53]. In a pilot study, nine patients re-
ceived myeloablative conditioning followed by UCB transplants 
with co-infusion of  MSCs and T-depleted HSC from a third-
party donor. All patients achieved neutrophil engraftment at a 
median of  12 days with full CB chimerism at a median of  51 
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days. The maximum cumulative incidence of  platelet engraft-
ment was 88% at a median of  32 days. However, no significant 
differences in UCB engraftment were observed if  compared to 
a control group of  46 transplants from the same center not re-
ceiving MSCs. Four patients in the MSC group developed grade 
II acute GVHD. Two patients who developed steroid-refractory 
GVHD were given repeated infusions of  MSCs and both showed 
complete remission. Last two achieved complete remission after 
therapeutic infusions of  MSCs [54]. In a similar study, 13 pediatric 
patients co-transplanted with UCB and parental MSCs, showed 
less grade III-IV GVHD and no significant disparity in engraft-
ment and grade II-IV acute GVHD compared to 39 matched his-
toric controls [55]. De Lima et al. [56] reported the results of  31 
patients receiving two CBUs, one of  which was co-cultured with 
MSCs ex vivo. The median TNC dose infused was 8.34 × 107/kg. 
This ex vivo culture system expanded TNC and CD34+ cells by a 
median factor of  12.2 and 30.1, respectively. Of  the 24 patients 
who received ex vivo expanded cells, 23 achieved neutrophil en-
graftment, at a median time of  15 days (range, 9-42 days), and 18 
had sustained platelet engraftment, at a median time of  42 days 
(range, 15-62 days). Although the expanded unit improves early 
hematopoietic recovery, it is the un-manipulated unit that usually 
provides long-term engraftment at 6 months [56]. These studies 
illustrated safety and efficacy in the presence of  third-party MSCs 
and confirm a potential role for UCB derived HSPC expansion 
methodologies.
Low molecular weight synthetic compounds
Another alternative strategy for the augmentation of  the hemat-
opoietic homing or proliferation potential is the brief  treatment 
of  the double UCB graft to small molecule modulators targeting 
to enhance hematopoietic engraftment. Direct addition of  small 
synthetic compounds to the culture medium is safe and easy ap-
proach in the light of  ex vivo expansion protocols.
Tetraethylenepentamine (TEPA): Out of  several LMW ago-
nists/antagonists screened and assessed for stem cell expansion; 
the most encouraging results were obtained in phase I trial with 
copper chelator, TEPA. It is based on the inherent property of  
copper deficiency to block hematopoietic maturation without 
affecting development of  progenitor cells [57]. Administration 
of  copper chelator, TEPA, in UCB derived CD34+ CD38- cells 
along with stimulatory cytokines (SCF, Flt-3 ligand, TPO and 
IL-6) promote CD34+ cells expansion by 17-fold at three weeks 
and 159-fold at seven weeks compared to input cell numbers [58]. 
TEPA mediated ex vivo expanded HSPCs showed improvement in 
NOD/SCID engraftment at eight weeks following transplanta-
tion [59, 60]. In a phase I/II clinical trial, single CD133+ cells were 
isolated from segregated portion of  UCB unit and expanded with 
early acting cytokines (SCF, Flt-3 ligand, TPO, IL-6 and TEPA)
for 21 days. The median TNC fold expansion was 219 (range, 
2-260). The expanded unit was infused 24 hrs after infusion of  
un-manipulated portion in 10 patients after myeloablative condi-
tioning. Despite the infusion of  a relatively low number of  total 
nucleated cells per kilogram (median of  1.8x107/kg), 9 of  the 10 
patients engrafted with a median time to neutrophil and platelet 
engraftment of  30 days (range, 16-46 ) and 48 days (range, 35-
105 ) respectively after transplantation. There was no increase in 
non-relapse mortality or the rate of  acute GVHD in comparison 
with historical controls. This approach showed no convalescence 
in the time to neutrophil or platelet engraftment compared with 
previous reports [61]. To further evaluate this approach, Gamida 
Cell performed prospective multicenter myeloablative UCBT trial 
(StemEx®) in 100 patients with advanced hematological malignan-
cies. Patients were transplanted with a single UCB unit of  which 
CD133+ cells from an aliquot of  the UCB unit (20-50%) and cul-
tured for 21 days with hematopoietic cytokines and TEPA and 
transplanted along with a minimum of  107 TNCs/ kg from the 
un-manipulated portion of  the same unit (NCT00469729). This 
study demonstrated the advantage of  StemEx® over dUCBT his-
torical controls, measured by a significant improvement in day 
100 survival (84% versus 72%) and faster early engraftment of  
neutrophils (21 versus 28 days) and platelets (54 versus 105 days). 
StemEx yielded a median of  14-fold increase in the number of  
CD34+ cells infused, in comparison to the number of  CD34+ cells 
the patients could have received from the entire un-manipulated 
CBU. Importantly, the CD34+ cell dose from the StemEx expand-
ed fraction was associated with time to neutrophil and platelet 
engraftment and inversely associated with grade III/IV infections 
during 100 day post-transplant. Out of  101 patients, 16 patients 
died in the first 100 days. This technical knowledge influences 
the venture of  increasing the number of  UCBT being performed 
while potentially diminishing its short term morbidity and mortal-
ity [62].
Prostaglandin E2: A conceivable modulator, the stable prosta-
glandin E2 (PGE2) derivative 16, 16-dimethyl PGE2 (dmPGE2), 
was previously identified in a chemical screen using zebra fish 
embryos to be a potent regulator of  vertebrate HSC homeosta-
sis. Mechanistically, dmPGE2 activates G-protein coupled pros-
taglandin receptors (PTGER2 and PTGER4) and consequently 
upregulate the expression of  genes involved in homing (eg, 
CXCR4), proliferation (eg, cyclinD1), self-renewal (Wnt signaling) 
and cell survival (eg, surviving) [63-65]. A recent study revealed 
PGE2 induce expression of  NR4A1 in long-term reconstituting 
hematopoietic stem cells which is closely associated with HSC 
quiescence and myeloid-biased HSCs [66]. Studies demonstrated 
the ability of  dmPGE2 to enhance hematopoietic engraftment 
of  HSCs [65, 67]. A phase I clinical trial evaluated the safety and 
efficacy using treatment with dmPGE2 ex vivo in 12 patients fol-
lowing reduced-intensity double UCBT. One of  two UCB units 
was incubated with a stable derivative of  PGE2 for two hours. 
The expanded unit dominated in 9 out of  11 evaluated patients. 
Results from this study demonstrated safety with accelerated neu-
trophil recovery (17.5 versus 21 days) of  the dmPGE2-treated 
UCB unit in 10 of  12 treated participants [68]. No instances of  
primary or secondary graft failure were observed [58]. A phase II 
study is currently under way [69].
Stemregenin: Aryl hydrocarbon receptor antagonist, stemre-
genin (SR1) was previously identified by microarray screening 
of  self-renewal regulators to be a potent enhancer of  human 
hematopoietic CD34+ cell numbers. Pre-clinical studies showed 
that 3 week culture of  HSCs with SR1 led to a 50-fold increase 
in CD34+ cells and a 17-fold increase in hematopoietic cells that 
retain the ability to engraft immunodeficient mice compared with 
uncultured cells or cells cultured with cytokines alone [70]. Aryl 
hydrocarbon receptors express on HSCs and are implicated in 
hematopoiesis regulating pathways such as HES-1, Pu.1, C/EBP-
beta, β-catenin and others. The precise mechanism whereby aryl 
hydrocarbon receptor inhibitor might induce HSPC self-renewal 
remains unknown. SR1 and Notch ligand delta1 synergistically 
enhance the number of  HSPCs [71]. Study showed that UCB cells 
cultured in combination with SR1, Delta1 and cytokines (IL-6, 
TPO, SCF, and Flt-3 ligand) for 14 to 16 days, lead to increase 
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in progenitors by 25-fold and decrease in differentiation to more 
mature myeloid cells. Furthermore, SR1 alone improved B-cell re-
population better than Delta1 or the combination of  Delta1 and 
SR1 in culture of  UCB cells [71]. This study showed economi-
cally feasible results to further develop cellular therapy to mitigate 
the risks associated with delayed myeloid recovery following UCB 
transplantation.
Nicotinamide: Study revealed that nicotinamide, a SIRT1 in-
hibitor, in co-culture with SCF, TPO, IL-6 and Flt3 ligand, facili-
tates expansion of  primitive progenitor cells (CD34+ CD38– and 
CD34+ CD38– Lin–) and enhanced myeloid and T-cell engraftment 
in murine models [72]. Encouraging results obtained in preclinical 
studies led to phase I/II clinical trials. A pilot study in 11 adult pa-
tients with haematological malignancy was transplanted with my-
eloablative double UCB unit (NCT01221857). CD133– cells were 
selected from one UCB unit for expansion and cryopreserved 
until transplant day, and were co-infused with the expanded UCB. 
CD133– fraction was co-infused to render original graft’s immu-
nocompetent T cells and NK cells to facilitate engraftment of  the 
UCB. Uncultured CD133– cells in combination with an enhanced 
HSPC dose following ex vivo expansion allows NiCord product 
for long-term engraftment. Study showed 486-fold expansion in 
neutrophils and 72-fold expansion in numbers of  CD34+ cells. 
The median time to engraftment was 13 days, with one patient 
developing graft failure. NiCord expansion also allowed choos-
ing a smaller but better HLA-matched UCB unit for transplanta-
tion. This has the potential to alleviate the frequency and severity 
of  GVHD and improve survival [30]. Extended follow-up with 
larger number of  patients is needed to confirm the safety and 
durability of  clinical cell product (Gamida-cell, Israel).
Notch mediated expansion of  UCB
In phase I trial, patients were given myeloablative conditioning, 
followed by infusion of  one un-manipulated UCB unit (2.4x105 
CD34+cells/kg) and second UCB unit that has undergone 164-
fold ex vivo expansion (6x106 CD34+ cells/kg) in the presence of  
immobilized Notch ligand and cytokines (SCF, Flt-3 ligand, TPO, 
IL-3 and IL-6) [7]. Median time to neutrophil recovery observed 
was 16 days (range, 7-34 ) in those receiving the expanded unit 
which was reportedly faster compared with 26 days (range, 23-
26 days) in a concurrent cohort of  20 patients receiving dUCBT 
with the same conditioning. Study demonstrated aggrandizement 
in neutrophil engraftment. Engraftment of  donor CD33+ and 
CD14+ cells predominated initially from the expanded UCB unit 
but disappeared in a few weeks in favor of  non-expanded UCB. 
Only half  of  the patients demonstrated predominant engraftment 
with the expanded UCB unit while another half  showed engraft-
ment from the un-manipulated unit, implying that the expand-
ed unit may have facilitated engraftment by the un-manipulated 
unit. No case of  engraftment failure was reported [7]. OS and 
GVHD risk were tantamount to those receiving un-manipulated 
UCB grafts. Phase II and III trials are required to further evaluate 
parameters of  occurrence of  infection, survival and duration of  
hospital stay in recipients of  UCB grafts.
Solutions to Clinical Challenges
Notwithstanding many encouraging clinical studies for upgrading 
engraftment rate following UCBT, challenges continue to exist. 
Delayed immune reconstitution following high-dose chemother-
apy and radiation for hematopoietic transplantation is a serious 
impediment to progress of  UCBT. Developing contemporary ap-
proach is to deplete selectively alloreactive T cells from the hap-
loidentical BM donor graft and host (to inhibit both GVHD and 
graft rejection) before transplantation. Another critical issue for 
achieving accelerated engraftment is the expansion of  the long-
term repopulating and mature HSPCs. A more likely advantage 
of  expansion is the ability to use smaller cord blood units, which 
could further increase the availability of  allografts. Notch-mediat-
ed expansion of  UCB progenitors led to the production of  large 
number of  short-term repopulating myeloid progenitor cells. 
However, analysis is tedious as involve infusion of  a second im-
munocompetent unit, resulting implausible long-term survival of  
the expanded cells. Exposure of  the graft to stemregenin showed 
considerable progress for expansion in early clinical trials. Com-
bination treatment of  donor UCB graft by either co-culture with 
MSCs, immobilized notch ligand or copper chelation followed by 
infusion of  these cells into conditioned recipients that are previ-
ously treated with stemregenin may be a better approach. It is 
important to consider cost-effective technologies to will affect the 
application of  stem cell expansion methodologies such as using 
closed and culture system of  bioreactors and 3-dimensional lat-
tices which allow effective utilization of  media and cytokines [73]. 
Nanofiber scaffold with different spacers based ex vivo expansion 
strategy for HSCs, while preserving their stem cell characteristics 
are undergoing progressive research [74]. Effective manipulation 
of  these events may provide UCBT more efficient and efficacious 
procedure. Still, expansion strategies are in multicenter trials, but 
none is as yet an established therapy.
Although hematopoietic cell expansion in UCB has shown im-
provements in engraftment but specific modification or modu-
lation of  homing and engraftment may serve as a possible di-
rect approach to make the limited number of  available HSPCs 
more efficient in homing and engraftment. It was examined that 
CD34+ cells from UCB show relatively weak affinity for the BM 
microvasculature as they contain reduced levels of  fucosylation 
of  E- and P-selectin ligands. In a clinical study (#NCT01471067), 
enforced fucosylation of  hematopoietic cells of  smaller of  the 
two UCB units, resulted in accelerated engraftment (17 days for 
neutrophils and 35 days for platelets). Though, later chimerism 
studies showed that unfucosylated unit dominated in about half  
the transplants [75]. Larger randomized studies will be required 
to confirm results in a larger data set and explore the mechanism 
of  enhancement of  engraftment. To evade the cell loss before 
homing, the concept of  direct micro-injection of  CD34+ UCB 
cells into the BM environment emerged. In Phase I/II trial, this 
technology was implemented in 32 patients with acute leukemia. 
All engrafted patients showed full donor chimerism [76]. Median 
time to neutrophil and platelet engraftment was 23 days (range 14-
44) and 36 days (range 16-64) respectively. Study established the 
safety and efficacy of  this procedure. Other experimental studies 
include inhibition of  dipeptidyl peptidase 4 (DPP4, expressed as 
CD26 on the cell surface) using small peptides or by deletion of  
CD26, and the upregulation of  CXCR4 expression. DPP4 cleaves 
the chemokine stromal cell-derived factor-1 (SDF-1), and trun-
cated SDF-1 antagonizes signals from full-length SDF-1α. DPP4 
inhibition enhance hematopoietic progenitor cell survival, ex vivo 
cytokine expansion, replating frequency, marrow homing and en-
graftment capability of  limiting numbers of  long-term repopu-
lating mouse HSCs into lethally irradiated mice [77]. Inhibition 
of  DPP4 also mediate SDF-1 independent effects as it enhances 
in vitro granulocyte-macrophage progenitor cell proliferation and 
also enhances recovery of  hematopoiesis after stress in vivo [78]. 
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Farag et al. evaluated the feasibility and potential efficacy of  sys-
temic inhibition of  DPP-4 using sitagliptin to enhance engraft-
ment of  single unit UCB grafts in adults with hematological ma-
lignancies (clinical trial NCT00862719). Clinical trial participants 
yielded favorable engraftment kinetics of  21 days, shorter time 
for engraftment than with single UCB transplantation reported 
in previous studies and showed cumulative incidence of  engraft-
ment of  94% at 50 days [79]. On the basis of  data from this clini-
cal trial, a semi-mechanistic model based approach was developed 
to understand sitagliptin concentration and DPP4 activity after 
single unit UCB transplantation. Simulations showed that twice or 
three times daily dosage schedules were better than a once daily 
schedule for maximal DPP4 inhibition at the lowest sitagliptin 
exposure. This study provides the first pharmacokinetic and phar-
macodynamic analysis of  sitagliptin and provides a valuable tool 
for optimization of  dose regimens and schedule to enhance en-
graftment after single UCB transplantation in adult patients [80].
Concluding Remarks
UCB graft is rapidly growing as significant HSC source for adults 
and remains an important mainstay for treatment in children by 
showing superior results. We have focused in this review on the 
results of  the various clinical trials to improve engraftment and 
the approaches to realize expansion strategies. Efforts focused 
on addressing cell dose limitations using ex vivo expansion and 
increased homing to assess safety and effectiveness are required 
to continue the advancement in the field of  UCBT. Exciting HSC 
expansion data with use of  direct addition of  extrinsic modula-
tors may be applicable to clinical settings in the near future. A po-
tential combination of  enhancement of  proliferation (using stem-
regenin, TEPA) and homing (eg PGE2, enhanced fucosylation, 
intrabone infusion, inhibition of  CD26, CXCR4 up-regulation) 
procedures may result in greater improvement in engraftment 
capacity than any one procedure itself. Homing procedures may 
be relatively inexpensive to perform and more widely used with-
out extensive ex vivo maneuvers or experience. Haematologists 
are trying to expand HSCs by exploring gene transfer strategies 
to manipulate HSCs for amplification. Future efforts to expand 
HSPCs to enhance the engrafting capabilities of  UCB cells will 
likely make use of  more in depth information on intracellular 
signaling molecules and their networks involved in hematopoi-
etic proliferation, survival, differentiation, homing and migration. 
Future studies may also develop alternative sources of  HSPCs, 
in particular embryonic stem cells or induced pluripotent stem 
cells, which may be amenable to many of  the expansion meth-
ods described herein. During the next few years, we may presume 
that expedited progress of  the encouraging procedures delineated 
herein will result in appreciably amplified production of  HSPCs 
for clinical implementation.
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